help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2007-0225
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pilli, T.
Right arrow Articles by Pacini, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pilli, T.
Right arrow Articles by Pacini, F.
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 9 3542-3546
Copyright © 2007 by The Endocrine Society

A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer

Tania Pilli, Ernesto Brianzoni, Francesca Capoccetti, Maria Grazia Castagna, Sara Fattori, Angela Poggiu, Gloria Rossi, Francesca Ferretti, Elisa Guarino, Luca Burroni, Angelo Vattimo, Claudia Cipri and Furio Pacini

Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry (T.P., M.G.C., E.G., C.C., F.P.), Section of Endocrinology and Metabolism, and Department of Radiology (L.B., A.V.), Section of Nuclear Medicine, University of Siena, 53100 Sienna, Italy; and Unit of Nuclear Medicine (E.B., F.C., F.F.) and Department of Fisica Sanitaria (S.F., A.P., G.R.), Hospital of Macerata, 62100 Macerata, Italy

Address all correspondence and requests for reprints to: Furio Pacini, M.D., Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy. E-mail: pacini8{at}unisi.it.

Objective: Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that 3700 MBq 131-iodine (131I) after recombinant human TSH (rhTSH) had a successful thyroid ablation rate similar to that obtained after thyroid hormone withdrawal. We investigated whether 1850 MBq 131I had a similar successful rate to 3700 MBq in patients prepared with rhTSH.

Design: A total of 72 patients with DTC were randomly assigned to receive 1850 (group A, n = 36) or 3700 MBq (group B, n = 36) 131I after rhTSH. One injection of 0.9 mg rhTSH was administered for 2 consecutive days; 131I therapy was delivered 24 h after the last injection, followed by a posttherapy whole-body scan. Successful ablation was assessed 6–8 months later.

Results: Successful ablation (no visible uptake in the diagnostic whole-body scan after rhTSH stimulation) was achieved in 88.9% of group A and B patients. Basal and rhTSH-stimulated serum thyroglobulin was undetectable (<1 ng/ml) in 78.9% of group A and 66.6% of group B patients (P = 0.46). Similar rates of ablation were obtained in both groups also in patients with node metastases.

Conclusion: Therapeutic 131I activities of 1850 MBq are equally effective as 3700 MBq for thyroid ablation in DTC patients prepared with rhTSH, even in the presence of node metastases.




This article has been cited by other articles:


Home page
Ann OncolHome page
F. Pacini, M. G. Castagna, L. Brilli, G. Pentheroudakis, and On behalf of the ESMO Guidelines Working Group
Differentiated thyroid cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv143 - iv146.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M Chianelli, V Todino, F M Graziano, C Panunzi, D Pace, R Guglielmi, A Signore, and E Papini
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
Eur. J. Endocrinol., March 1, 2009; 160(3): 431 - 436.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. W. Rosario, M. A. R. Borges, and S. Purisch
Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity
J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. Remy, I. Borget, S. Leboulleux, N. Guilabert, F. Lavielle, J. Garsi, C. Bournaud, S. Gupta, M. Schlumberger, and M. Ricard
131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients
J. Nucl. Med., September 1, 2008; 49(9): 1445 - 1450.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society